Cariprazine is an atypical antipsychotic acting as a D3/D2 receptor partial agonist and 5-HT1A partial agonist, with preferential D3 selectivity that distinguishes it among antipsychotics, used for schizophrenia and bipolar disorder. Simson Pharma's Cariprazine reference standard and impurities support stability-indicating method development for this newer-generation antipsychotic.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Cariprazine Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.